KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.00 USD
-0.15 (-2.44%)
Updated Jun 13, 2024 03:50 PM ET
After-Market: $6.02 +0.02 (0.33%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth B Momentum D VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 221 - 240 ( 365 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Fallout Has Little Impact on Overall Valuation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
STRIDE 3 Delivers; EYSUVIS Resubmission in 2Q20; Raising PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Plenty of Cash to Cover Key Catalysts; Next: Resubmission of DED NDA in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L